Compare SMID & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | VYGR |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.8M | 222.4M |
| IPO Year | 1995 | 2015 |
| Metric | SMID | VYGR |
|---|---|---|
| Price | $35.80 | $3.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 5.4K | ★ 745.6K |
| Earning Date | 11-13-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $25.13 | $2.65 |
| 52 Week High | $43.66 | $5.73 |
| Indicator | SMID | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.11 |
| Support Level | N/A | $3.51 |
| Resistance Level | N/A | $4.09 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 11.89 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.